153023 Medications for Treatment of Mental Illness:Physician Prescribing Patterns and Their Implications

Monday, November 5, 2007: 1:06 PM

Katharine Levit, BS , Behavioral Health and Quality Research, Thomson Reuters, Washington, DC
Tami L. Mark, PhD , Research & Pharmaceutical, Thomson Medstat Inc., Washington, DC
Cheryl Kassed, PhD , Behavioral Health and Quality Research, Thomson Reuters, Washington, DC
Jeffrey A. Buck, PhD , Center for Mental Health Services, Substance Abuse and Mental Health Services Administration, Rockville, MD
Rosanna Coffey, PhD , Thomson Medstat, Washington, DC
Using transaction records on prescriptions filled at retail pharmacies, we will present recent trends in prescribing by primary care provider (PCPs), psychiatric physicians, and all other specialties for groups of drugs widely recognized in the treatment of MH conditions. We find that primary care providers prescribe over half of all mental health drugs, including 6 out of every 10 prescriptions written for antidepressants and for anxiolytic, sedative hypnotics used to treat anxiety and sleep disorders. Drug prescribing for antipsychotics and antimanics primarily prescribed for schizophrenia and bipolar disease continues to be dominated by psychiatrists. However, the growth of managed care and managed behavioral health organizations, availability of drugs with fewer side effects, and direct-to-consumer advertising have pushed more prescribing of MH drugs into the primary care arena, creating opportunities for increased access for consumers and potential challenges in quality of MH treatment.

Learning Objectives:
Articulate the current and past substance abuse and mental health medication prescribing patterns and drivers of past and future prescribing trends.

Keywords: Medicine, Mental Illness

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.